Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2006 1
2010 1
2013 1
2014 1
2015 1
2017 1
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
A genomics-based classification of human lung tumors.
Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). Clinical Lung Cancer Genome Project (CLCGP), et al. Sci Transl Med. 2013 Oct 30;5(209):209ra153. doi: 10.1126/scitranslmed.3006802. Sci Transl Med. 2013. PMID: 24174329 Free PMC article.
Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.
Jawhar M, Naumann N, Schwaab J, Baurmann H, Casper J, Dang TA, Dietze L, Döhner K, Hänel A, Lathan B, Link H, Lotfi S, Maywald O, Mielke S, Müller L, Platzbecker U, Prümmer O, Thomssen H, Töpelt K, Panse J, Vieler T, Hofmann WK, Haferlach T, Haferlach C, Fabarius A, Hochhaus A, Cross NCP, Reiter A, Metzgeroth G. Jawhar M, et al. Among authors: topelt k. Ann Hematol. 2017 Sep;96(9):1463-1470. doi: 10.1007/s00277-017-3067-x. Epub 2017 Jul 19. Ann Hematol. 2017. PMID: 28725989 Clinical Trial.
Identification and functional characterization of imatinib-sensitive DTD1-PDGFRB and CCDC88C-PDGFRB fusion genes in eosinophilia-associated myeloid/lymphoid neoplasms.
Gosenca D, Kellert B, Metzgeroth G, Haferlach C, Fabarius A, Schwaab J, Kneba M, Scheid C, Töpelt K, Erben P, Haferlach T, Cross NC, Hofmann WK, Seifarth W, Reiter A. Gosenca D, et al. Among authors: topelt k. Genes Chromosomes Cancer. 2014 May;53(5):411-21. doi: 10.1002/gcc.22153. Genes Chromosomes Cancer. 2014. PMID: 24772479
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.
Scheffler M, Bos M, Gardizi M, König K, Michels S, Fassunke J, Heydt C, Künstlinger H, Ihle M, Ueckeroth F, Albus K, Serke M, Gerigk U, Schulte W, Töpelt K, Nogova L, Zander T, Engel-Riedel W, Stoelben E, Ko YD, Randerath W, Kaminsky B, Panse J, Becker C, Hellmich M, Merkelbach-Bruse S, Heukamp LC, Büttner R, Wolf J. Scheffler M, et al. Among authors: topelt k. Oncotarget. 2015 Jan 20;6(2):1315-26. doi: 10.18632/oncotarget.2834. Oncotarget. 2015. PMID: 25473901 Free PMC article.
Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection.
Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyiannis DP, Töpelt K, Courtney R, Wexler D, Krishna G, Martinho M, Corcoran G, Raad I. Ullmann AJ, et al. Among authors: topelt k. Antimicrob Agents Chemother. 2006 Feb;50(2):658-66. doi: 10.1128/AAC.50.2.658-666.2006. Antimicrob Agents Chemother. 2006. PMID: 16436724 Free PMC article. Clinical Trial.
Osteoblastic response in patients with non-small cell lung cancer with activating EGFR Mutations and bone metastases during treatment with EGFR kinase inhibitors.
Ansén S, Bangard C, Querings S, Gabler F, Scheffler M, Seidel D, Saal B, Zander T, Nogová L, Töpelt K, Markert E, Stoelben E, Ernestus K, Thomas RK, Wolf J. Ansén S, et al. Among authors: topelt k. J Thorac Oncol. 2010 Mar;5(3):407-9. doi: 10.1097/JTO.0b013e3181cf32aa. J Thorac Oncol. 2010. PMID: 20186030 Free article. No abstract available.